{
    "links": "https://www.ycombinator.com/companies/circumvent",
    "name": "Circumvent",
    "headline": "Utilizing monogenic disorders to inform and solve highly complex\u00e2\u0080\u00a6",
    "batch": "S18",
    "description": null,
    "activity_status": "Active",
    "website": "https://www.circumventpharmaceuticals.com/",
    "founded_date": null,
    "team_size": 6.0,
    "location": null,
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:neurotechnology; industry:biotech; industry:genomics",
    "founders": [],
    "status": true,
    "generated_description": "**Company Overview: Circumvent Pharmaceuticals**\n\n**Mission:** Circumvent Pharmaceuticals is on a critical mission to leverage monogenic disorders as a lens to inform and address complex issues in neurodegenerative diseases. Essentially, they're looking to harness insights from rare diseases to develop targeted therapies that could change the game in treating common neurological conditions.\n\n**Background:** Founded as part of Y Combinator Batch S18, Circumvent focuses specifically on creating precision medicines for neurodegenerative diseases like Batten Disease\u2014an area often neglected in mainstream medicine. Their approach is rooted in understanding the intricate biological processes underlying these disorders, thus paving the way for innovative treatments.\n\n**Location and Team:** Although specific location details weren't provided, Circumvent operates with a dedicated team of six professionals who are committed to advancing research and treatment options in the biotech space.\n\n**Core Focus Areas:** Tagged as a startup working in the realms of neurotechnology, biotech, and genomics, Circumvent aims to unravel the complexities of neurological disorders through research, particularly with high-fidelity animal models that provide predictive insights into clinical outcomes.\n\n**Strategic Approach:**\n- **Precision Medicine:** Circumvent tackles diseases like Batten Disease, a rapidly progressing neurological disorder that currently has no approved treatments, with an understanding gained through genetics and disease mechanisms.\n- **Innovation in Drug Development:** By studying the palmitoylome (which involves fatty acids\u2019 role in brain function) and synaptic architecture, Circumvent is uncovering new strategies that could lead to effective therapies not only for rare diseases like CLN1 Batten Disease but potentially for a range of common neurodegenerative disorders.\n\n**Patient-Centric Development:** Circumvent is deeply entrenched in listening to patients and caregivers, aiming to align their research with the real needs and expectations of those affected by these challenging conditions. This engagement helps guide their R&D efforts and ensures a focus on impactful results.\n\n**Collaborations and Advocacy:** They partner with advocacy organizations for Batten Disease to foster support and research efforts, recognizing the importance of community and shared knowledge in advancing drug development.\n\n**Get Involved:** If you\u2019re a stakeholder in the realm of rare genetic disorders, Circumvent is open to dialogue. Their website offers more avenues to connect, either for patients, caregivers, or potential partners.\n\n**Conclusion:** Circumvent Pharmaceuticals stands at the intersection of innovation and necessity, taking a focused approach to develop treatments for debilitating neurodegenerative diseases while rooted in a patient-first methodology. Their work could be crucial in changing the way we approach therapies for some of the most challenging health issues of our time. For more information, check out their website [here](https://www.circumventpharmaceuticals.com/).",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/bc59c9fd64827edf3d2e0efc69702b7cbdec7d0c.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAEHIR6H6F%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191050Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDt736ZW5EfzagAz1eKRSs%2FW4TfHu28RBSFaRNkZ9h47gIhANt6WXtwkgL07bQKDKYDGFxYKx7WOO9JX0BqaYrXnKNbKu4DCNz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMMDA2MjAxODExMDcyIgx8TqkMwTM2PLcRmr4qwgPGGtQBXv7gs7%2BXGteI1gQk%2FjkbIHwQ5hCKXJKVmVAPw3MeVLhZyp8Nf5%2FYigbwE%2BrFR7aZWKjrs7HxAE0JWit5dlINZLjZK%2BS%2FwMaCqoj%2BFDN0gw9iiAPu4Xn5c3b%2BuZe%2F5%2Flfk0EuxZAXVsZtShxXZy%2FERPQ0v%2FRZxSz5qUoaXpL1zj6VWdWVzoI7%2FPlB3bgJ2PpiF7DN%2BJeDsJPx%2FoKTo5ehP9pOeGbMNxoeegVJsCJ3zvzO3o4fcZYIf6c5iIJwM1Ot3Gg7Z3v9oLZjSRU%2FaRLL5j4n3II7DaroOCEVfPlWzTyZM7SNFZZAFSKM8vLKj1VdTr9s3How41zluf%2FOIp7sGNhG%2FjuYJoG%2FmkLFIlYP4wbGrLO69AWnenZyfi1UhAiV6N%2BlAqGnqvpOJh4vq8uNh2eRnXR%2BMVXdq9oVYkm7XFgprL5PDC4ULLyBWqA6kca4z7F4H56nkT%2FsDtT8ek2VOIRIv1Zgcz%2BeeVG7F7AHS4bdbR6eZ3ChY1iQhfPBErh4OiFQM7IqiUKw%2B1CTpvL68xcVN5gjiaDH0Jotw%2BUcW9dMSg9py8xH8qgyiWG5w3dDj9xaoA2G3NMYq6JOGKMwwIrjvQY6pAHDH54nhADhmb7YSEGxHkL3pqs%2B6aYOExStWbzLKzRb3lb2DAgGG8uU9COt8%2FqUEOtOcszTKp7yuCJwMVkfI7PDZ74h9uiRkRxjtH7%2BLlE1xrfd%2FrIq%2B%2BZr9hSFqZ9MUQ4yNHesyx2FYDbsIfCW9ntlrpmZUHCcrzpQDfufsAFcpe%2FudVT3tUqiF8WCN1Vd%2Bx%2FQ9d3i1HvBcJWV9AYAwM0W22VM%2BA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=d29d028eae29937ca7815477152a819bd22f779d9f707eaed3c18c1c26ad508d",
    "social_links": [
        "https://www.crunchbase.com/organization/circumvent-pharmaceuticals"
    ],
    "logo_path": "data/logos\\Circumvent_logo.png"
}